Liquidia Corporation To Present At 44Th Annual J.P. Morgan Healthcare Conference

(MENAFN- GlobeNewsWire - Nasdaq) MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 beginning at approximately 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California.

Access to a live, audio-only webcast will be available on the“Investors” page of Liquidia's website at . The webcast will be archived on the company's website for at least 30 days.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT^®Technology. PRINT enabled the creation of Liquidia's first approved product, YUTREPIATM (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit .

Contact Information

Investors:
Jason Adair
Chief Business Officer
919.328.4400
...

Media:
Patrick Wallace
Director, Corporate

MENAFN07012026004107003653ID1110567101